Seminal
The magazine and atlas of EU-funded researchA new publication from the web and AI team at Scott Charnley

Atlas / France

Research and Innovation Action · Running

HENIPROTECT EU-HENIpavirus PROTECTion via inhaled antibody solution

Coordinator
Institut National De La Sante Et De La Recherche Medicale, France
Runs
1 September 2026 to 31 August 2032
Status
Running
EU funding
€16.3m
Total cost
—
Partners
20 organisations in 8 countries
Type
Research and Innovation Action
Grant agreement
101286662

What the project is doing

In the project's own words, from its summary on CORDIS.

HENIPROTECT addresses the urgent need for effective countermeasures against Henipaviruses, in particular Nipah virus (NiV). With its high mortality rate and proven human-to-human transmission, NiV represents a global health security concern with limited treatment options. HENIPROTECT aims to deliver the first inhaled antibody(Ab)-based treatment of NiV infection, expandable to another lethal Henipavirus, Hendra virus.

The project will advance the most promising humanized Ab candidate (derived from murine Nip35 specific for NiV fusion protein) to first-in-human clinical trial, and lay the foundation for an Ab cocktail combining Nip35 and another Ab that blocks NiV entry through complementary mechanism, providing a dual-target approach for a broad protection against NiV. By targeting the respiratory tract—the main site of infection and transmission—the inhaled formulation will offer direct protection, blocking viral replication and spread.

To achieve this, the consortium will finalize preclinical characterization of the Ab candidates, optimize their formulation for inhaled delivery through mesh-nebulization and establish regulatory-compliant production processes, including GMP manufacturing. Pharmacokinetic and toxicology studies, supported by modelling platforms, will guide safe clinical translation. Parallel efforts will adapt a cost-effective inhalation device, establish an alternative microalgae-based production platform, and create a flexible Ab toolbox to counter emerging viral variants, ensuring affordability, scalability and long-term resilience.

HENIPROTECT fully aligns with the EU work programme priorities on health security and pandemic preparedness, by supporting innovation in biomanufacturing and enabling equitable access to life-saving countermeasures. By combining cutting-edge science with scalable production and affordable delivery, the project strengthens Europe’s capacity to respond swiftly to viral outbreaks, reinforcing the global health security.

Topics

Who is involved

OrganisationCityCountryRole
Institut National De La Sante Et De La Recherche MedicaleParisFranceCoordinator
European Research Infrastructure on Highly Pathogenic AgentsBruxelles / BrusselBelgiumParticipant
Centre Hospitalier Universitaire VaudoisLausanneSwitzerlandParticipant
European Respiratory SocietyLausanneSwitzerlandParticipant
Lascco SAEpalingesSwitzerlandParticipant
Freie Universitaet BerlinBerlinGermanyParticipant
Twincore, Zentrum Fur Experimentelle Und Klinische InfektionsforschunggmbhHannoverGermanyParticipant
Universitaet BielefeldBielefeldGermanyParticipant
Centre Hospitalier Regional Universitaire De ToursTours Cedex 9FranceParticipant
Inserm Transfert SAParisFranceParticipant
MabsilicoToursFranceParticipant
MabDesignLyonFranceParticipant
Universite De ToursToursFranceThird party
Universite Paris Xii Val De MarneCreteilFranceParticipant
Nemzeti Nepegeszsegugyi Es Gyogyszereszeti KozpontBudapestHungaryThird party
Aerogen LtdGalwayIrelandParticipant
Cytiva Testa Center ABUppsalaSwedenParticipant
Kungliga Tekniska HoegskolanStockholmSwedenParticipant
Northx Biologics Matfors ABMatforsSwedenParticipant
European Lung FoundationSheffieldUnited KingdomParticipant

Source: CORDIS, European Commission. Data of 5 Nov 2026, reused under the Commission's reuse policy. View on CORDIS · Grant DOI